What Is Adagrasib
Adagrasib is a targeted agent directed against KRAS G12C mutation, mainly used for the treatment of non small cell lung cancer (NSCLC) and other solid tumors harboring this mutation.
It irreversibly binds and inhibits the activity of the mutant KRAS protein, blocks downstream oncogenic signaling pathways, and thereby suppresses tumor growth.The drug has demonstrated significant efficacy in clinical trials and has been approved in several countries for specific indications.
Side Effects and Safety
Common Side Effects
Common adverse reactions of adagrasib include gastrointestinal symptoms (nausea, diarrhea), fatigue, and elevated liver enzymes.
Serious Side Effects
Serious adverse reactions may involve cardiac toxicity (such as QT interval prolongation) and interstitial lung disease.Regular ECG and liver function monitoring are required.Most adverse reactions are mild to moderate and can be managed by dose adjustment or symptomatic treatment.
Drug Resistance and Combination Therapy
Although adagrasib demonstrates significant efficacy, drug resistance may develop in some patients.Resistance mechanisms may involve feedback activation of the KRAS signaling pathway or secondary gene mutations.Current research supports combination treatment strategies, including:
Combination with EGFR Inhibitors
Blocking EGFR signaling reduces KRAS‑dependent bypass pathway activation.
Combination with SHP2 Inhibitors
Inhibition of the SHP2 protein enhances blockade of the KRAS pathway.
Combination with Immunotherapy
Improves anti‑tumor efficacy by enhancing the response of the immune microenvironment.
Research Progress and Future Directions
Adagrasib was granted accelerated approval by the U.S. FDA in 2022 for the second‑line treatment of KRAS G12C‑mutated NSCLC.Multiple Phase III clinical trials (such as the KRYSTAL‑12 study) are ongoing to evaluate its potential as first‑line therapy in lung cancer and colorectal cancer.Future research will focus on optimizing administration strategies, expanding indications, and overcoming drug resistance.
Eligible Patients and Dosing Recommendations
Adagrasib is indicated only for patients with advanced solid tumors confirmed to harbor the KRAS G12C mutation by genetic testing.Before treatment, comprehensive evaluation of the patient’s performance status, comorbidities, and drug interactions is required.Close follow‑up is necessary during treatment, with dynamic assessment of efficacy and resistance through imaging examinations and liquid biopsies.
